Oncology Institute Stock Performance
| TOI Stock | USD 1.00 0.04 4.17% |
Oncology Institute holds a performance score of 25 on a scale of zero to a hundred. The company holds a Beta of 2.34, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncology Institute will likely underperform. Use Oncology Institute kurtosis, day typical price, as well as the relationship between the potential upside and total risk alpha , to analyze future returns on Oncology Institute.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oncology Institute are ranked lower than 25 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Oncology Institute demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 14 M |
Oncology |
Oncology Institute Relative Risk vs. Return Landscape
If you would invest 20.00 in Oncology Institute on December 22, 2024 and sell it today you would earn a total of 80.00 from holding Oncology Institute or generate 400.0% return on investment over 90 days. Oncology Institute is generating 3.1502% of daily returns assuming volatility of 9.626% on return distribution over 90 days investment horizon. In other words, 85% of stocks are less volatile than Oncology, and above 37% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Oncology Institute Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Institute's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncology Institute, and traders can use it to determine the average amount a Oncology Institute's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.3273
| Best Portfolio | Best Equity | |||
| Good Returns | TOI | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.63 actual daily | 85 85% of assets are less volatile |
Expected Return
| 3.15 actual daily | 63 63% of assets have lower returns |
Risk-Adjusted Return
| 0.33 actual daily | 25 75% of assets perform better |
Based on monthly moving average Oncology Institute is performing at about 25% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncology Institute by adding it to a well-diversified portfolio.
Oncology Institute Fundamentals Growth
Oncology Stock prices reflect investors' perceptions of the future prospects and financial health of Oncology Institute, and Oncology Institute fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncology Stock performance.
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 145.89 M | ||||
| Shares Outstanding | 75.56 M | ||||
| Price To Earning | 190.67 X | ||||
| Price To Book | 4.54 X | ||||
| Price To Sales | 0.19 X | ||||
| Revenue | 324.24 M | ||||
| EBITDA | (70.45 M) | ||||
| Cash And Equivalents | 64.21 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 119.67 M | ||||
| Debt To Equity | 0.15 % | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (36.31 M) | ||||
| Earnings Per Share | (0.77) X | ||||
| Total Asset | 209.24 M | ||||
| Retained Earnings | (146.15 M) | ||||
About Oncology Institute Performance
By evaluating Oncology Institute's fundamental ratios, stakeholders can gain valuable insights into Oncology Institute's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncology Institute has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncology Institute has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 658 people.Things to note about Oncology Institute performance evaluation
Checking the ongoing alerts about Oncology Institute for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncology Institute help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncology Institute is way too risky over 90 days horizon | |
| Oncology Institute has some characteristics of a very speculative penny stock | |
| Oncology Institute appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 324.24 M. Reported Net Loss for the year was (83.07 M) with profit before taxes, overhead, and interest of 53.74 M. | |
| Oncology Institute has about 64.21 M in cash with (36.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Oncology Institute's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncology Institute's stock is overvalued or undervalued compared to its peers.
- Examining Oncology Institute's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncology Institute's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncology Institute's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncology Institute's stock. These opinions can provide insight into Oncology Institute's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |